Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 7^thEdition

Matrix-dependent absorption of 8–methoxypsoralen in extracorporeal photopheresis

“…Extracorporeal photopheresis (ECP) is a well-established therapy for various immunological diseases such as cutaneous T-cell lymphoma, graft-versus-host-disease or solid organ transplant rejection. [1][2][3] In this three-stage procedure, autologous leukocytes are collected (leukapheresis), incubated ex vivo with photoactive 8-methoxypsoralen (8-MOP) and subsequently exposed to UVA ( photoactivation) before being returned to the patient (reinfusion). Leukocyte apheresis and photoactivation may be integrated into a single system (inline) or performed on two separate systems (offline).…”

Plasmapheresis as an Early Treatment for Severe Hypertriglyceridemia, Acute Pancreatitis, and Diabetic Ketoacidosis

“…As a result, 21 hours after admission he received his first course of plasmapheresis, dramatically decreasing triglycerides to 451 mg/dL and improving his pain. He received a second course of plasmapheresis at 40 hours based on current practice guidelines [4], which decreased triglycerides to 69 mg/dL. He started a low-fat diet 42 hours after admission, which he tolerated well.…”

Blood apheresis technologies – a critical review on challenges towards efficient blood separation and treatment

“…31 An analysis of the key performance characteristics of each apheresis techniques is therefore required 27 and must be tailored to a specific disease indication. [32][33][34] This review discusses current blood apheresis technologies as well as emerging solutions and materials to separate specific components from blood. A comprehensive overview on the gaps remaining across these technologies in terms of extraction rate, separation yield, throughput and potential effects on cells will be presented.…”